Q-omics provides the consensus-scored MTERF2 profile across patient tissues and cancer cell-line models. MTERF2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, MTERF2 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, MTERF2 RNA expression shows 20,580 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, LIHC, and UVM as cancer lineages where MTERF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTERF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTERF2 survival associations across molecular data types. MTERF2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTERF2 RNA expression–survival associations across cancer types. High MTERF2 expression shows unfavorable associations in COAD, KIRC and KICH, but favorable associations in BLCA, PAAD and BRCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for MTERF2 RNA expression.
This table summarizes MTERF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MTERF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTERF2 shows lower tumor expression in THCA, LUAD, KICH, LUSC and KIRC and higher tumor expression in LIHC. The LIHC box plot shows higher MTERF2 RNA expression in tumor versus normal tissue (log2 FC = +0.743, t-test p < 0.001).
This table shows molecular features associated with MTERF2 in patient tissues and cancer cell lines. In patient samples, MTERF2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MTERF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT.
